Novel lactic acid bacteria Lactiprantibacillus plantarum SKO-001 for reducing body fat and its use

Abstract

The present invention relates to a novel lactic acid bacterium, Lactiprantibacillus plantarum SKO-001, for reducing body fat and uses thereof.

Description

[Technical Field]

[0001] The present invention relates to a novel lactic acid bacterium, Lactiprantibacillus plantarum SKO-001, for reducing body fat and uses thereof. [Background technology]

[0002] Body fat is the adipose tissue that makes up the body. It is widely distributed under the skin, in the mammary glands, around the kidneys, etc., and serves the functions of storing fat and using it as energy, as well as protecting internal organs and regulating body temperature. Adipose tissue is primarily composed of fat cells and water, and it is known that 1 kg of fat can be converted into approximately 7,300 kcal of energy. An adult has approximately 6 to 25 kg of such adipose tissue.

[0003] Thus, fat is important as an energy source and also in homeostatic regulation, but excessive accumulation of fat leads to obesity, and in particular, accumulation of intraperitoneal visceral fat is known to cause insulin resistance and increased fat synthesis in the liver, leading to glucose and lipid metabolism disorders, hypertension, coronary artery disease, etc. In particular, in modern times, changes in eating habits have led to an increase in the excessive accumulation of body fat, obesity, and various resulting diseases, and the importance of reducing or regulating body fat, along with the treatment of obesity, is becoming increasingly important.

[0004] Obesity treatment methods include diet and exercise therapy, surgical therapy, and drug therapy. Among these, diet and exercise therapy involves a low-calorie, low-fat intake and physical activity that consumes oxygen. However, this requires patient, repeated, and continuous practice, and is therefore considered to be difficult to achieve widespread effectiveness. Surgical therapy involves the physical removal of body fat through surgery, and has the advantage of achieving results in a short period of time. However, its use is limited due to resistance to surgery, poor durability of results, and a large economic burden. Drug therapy is a method of treating or preventing obesity using drugs that suppress appetite or inhibit fat absorption, but it is problematic due to the numerous side effects, such as depression and rebound effects. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Korean Patent Registration No. 10-2163551 (October 7, 2020) Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, there is still a need to develop alternative agents that can guarantee long-term body fat reduction effects and have fewer side effects. [Means for solving the problem]

[0007] The present invention provides a food composition for reducing body fat, which contains at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0008] The present invention also provides a food composition for preventing or improving obesity, which contains at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0009] Furthermore, the present invention provides a pharmaceutical composition for preventing or treating obesity, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0010] Furthermore, the present invention provides a feed composition for preventing or improving obesity, which comprises at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0011] Furthermore, the present invention provides a food composition for preventing or improving metabolic diseases, which contains at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0012] Furthermore, the present invention provides a pharmaceutical composition for preventing or treating metabolic diseases, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0013] Furthermore, the present invention provides a feed composition for preventing or improving metabolic diseases, which comprises at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0014] Furthermore, the present invention provides a use of a composition containing at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof for reducing body fat.

[0015] Furthermore, the present invention provides a use of a composition containing at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof for preventing, improving, or treating obesity.

[0016] Furthermore, the present invention provides a use of a composition containing at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof for preventing, improving, or treating a metabolic disease.

[0017] Furthermore, the present invention provides a method for reducing body fat, which comprises administering a composition containing at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0018] Furthermore, the present invention provides a method for preventing, improving, or treating obesity, which includes a step of administering a composition containing at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0019] Furthermore, the present invention provides a method for preventing, ameliorating, or treating a metabolic disease, which comprises administering to an individual a composition containing at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0020] According to one embodiment of the present invention, there is provided a food composition for reducing body fat, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0021] According to one embodiment of the present invention, the strain may be Lactiplantibacillus plantarum SKO-001 strain deposited under accession number KCTC 14816BP.

[0022] According to one embodiment of the present invention, the strain may have a 16S rRNA sequence represented by SEQ ID NO:1.

[0023] According to one embodiment of the present invention, there is provided a food composition for preventing or improving obesity, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0024] According to one embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating obesity, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0025] According to one embodiment of the present invention, there is provided a feed composition for preventing or improving obesity, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0026] According to one embodiment of the present invention, there is provided a food composition for preventing or improving metabolic diseases, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0027] According to one embodiment of the present invention, the metabolic disease may be at least one selected from the group consisting of obesity, diabetes, insulin resistance, dyslipidemia, hypercholesterolemia, arteriosclerosis, hepatic steatosis, fatty liver, and cardiovascular disease.

[0028] According to one embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating metabolic diseases, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0029] According to one embodiment of the present invention, there is provided a feed composition for preventing or improving metabolic diseases, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof. [Effects of the Invention]

[0030] According to one embodiment of the present invention, the lactic acid bacterium of the present invention, Lactiplantibacillus plantarum SK0-001, exhibits excellent effects in reducing body fat and weight, reducing blood cholesterol, and improving fatty liver, and is useful for preventing, treating, and improving obesity and lipid-related metabolic diseases. [Brief explanation of the drawings]

[0031] [Figure 1] This figure shows the results of measuring body weight changes in C57BL / 6J mice (6-week-old, male) that were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet, and whose body weight was measured once a week at the same time. Statistical analysis was performed as follows: Student's t test ***p<0.005 vs CTL #p<0.05 vs HFD [Figure 2]This figure shows the results of measuring food intake. C57BL / 6J mice (6-week-old, male) were orally administered the test substance once a day for 12 weeks, starting 3 weeks after being fed a high-fat diet, and food intake was measured once a week at the same time. Here, food intake was calculated by subtracting the amount of food remaining from the amount of food provided. Statistical analysis was performed as follows: Student's t test ***p<0.005 vs CTL ns; not significant [Figure 3] This figure shows the results of measuring body fat mass using Minispec. Statistical analysis was performed as follows: Student's t test ***p<0.005 vs CTL #p<0.05 vs HFD [Figure 4a] This figure shows the results of analyzing blood energy metabolism regulatory factors (insulin, adiponectin, leptin). Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet, and blood was collected after overnight fasting to measure blood energy metabolism regulatory factors (insulin, adiponectin, leptin). Statistical analysis was performed as follows: Student's t test ***p<0.005 vs CTL #p<0.05, ##p<0.01, ###p<0.005 vs HFD [Figure 4b] This figure shows the results of analyzing lipid (total cholesterol, LDL-c, HDL-c, TG, FFA) concentrations. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet, and blood samples were collected after overnight fasting to measure lipid (total cholesterol, LDL-c, HDL-c, TG, FFA) concentrations. Statistical analysis was performed as follows: Student's t test ***p<0.005 vs CTL #p<0.05, ##p<0.01, ###p<0.005 vs HFD [Figure 5a]This figure shows the results of H&E staining in a morphological study of adipose tissue, specifically, the results for subcutaneous adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting from 3 weeks after feeding a high-fat diet. After overnight fasting, the morphology of adipocytes in subcutaneous adipose tissue was measured by H&E staining. [Figure 5b] This figure shows the results of H&E staining in a morphological study of adipose tissue, specifically, the results for visceral adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting from 3 weeks after feeding a high-fat diet. After overnight fasting, the morphology of adipocytes in visceral adipose tissue was measured by H&E staining. [Figure 5c] This figure shows the results of H&E staining in a morphological study of adipose tissue, specifically, the results for epididymal adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting from 3 weeks after feeding a high-fat diet. After overnight fasting, the morphology of adipocytes in epididymal adipose tissue was measured by H&E staining. [Figure 6a] This figure shows the results of analyzing the mRNA expression of adipocyte differentiation-related factors (SREBP1, PPARγ, and C / EBPα) in adipose tissue, specifically the results for subcutaneous adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, each adipose tissue was collected and the mRNA levels of transcription factors involved in adipocyte differentiation (SREBP1, PPARγ, and C / EBPα) were measured by real-time qPCR. Statistical analysis was performed as follows: Student's t test *p<0.05, **p<0.01, ***p<0.005 vs. CTL #p<0.05, ##p<0.01, ###p<0.005 vs. HFD [Figure 6b]This figure shows the results of analyzing the mRNA expression of adipocyte differentiation-related factors (SREBP1, PPARγ, and C / EBPα) in adipose tissue, specifically the results for visceral adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, each adipose tissue was collected and the mRNA levels of transcription factors involved in adipocyte differentiation (SREBP1, PPARγ, and C / EBPα) were measured by real-time qPCR. Statistical analysis was performed as follows: Student's t test *p<0.05, **p<0.01, ***p<0.005 vs. CTL #p<0.05, ##p<0.01, ###p<0.005 vs. HFD [Figure 6c] This figure shows the results of analyzing the mRNA expression of adipocyte differentiation-related factors (SREBP1, PPARγ, and C / EBPα) in adipose tissue, specifically the results for epididymal adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, each adipose tissue was collected and the mRNA levels of transcription factors involved in adipocyte differentiation (SREBP1, PPARγ, and C / EBPα) were measured by real-time qPCR. Statistical analysis was performed as follows: Student's t test *p<0.05, **p<0.01, ***p<0.005 vs. CTL #p<0.05, ##p<0.01, ###p<0.005 vs. HFD [Figure 7a] This figure shows the results of analyzing the mRNA expression of thermogenesis-related factor (UCP1) in adipose tissue, specifically the results for subcutaneous adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, each adipose tissue was collected and the mRNA level of thermogenesis-related factor (UCP1) was measured by real-time qPCR. Statistical analysis was performed as follows: Student's t test *p<0.05, **p<0.01 vs. CTL #p<0.05, ##p<0.01, ###p<0.005 vs. HFD [Figure 7b] This figure shows the results of analyzing the expression of thermogenesis-related factor (UCP1) mRNA in adipose tissue, specifically the results for visceral adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, each adipose tissue was collected and the mRNA level of thermogenesis-related factor (UCP1) was measured by real-time qPCR. Statistical analysis was performed as follows: Student's t test *p<0.05, **p<0.01 vs. CTL #p<0.05, ##p<0.01, ###p<0.005 vs. HFD [Figure 7c] This figure shows the results of analyzing the mRNA expression of thermogenesis-related factor (UCP1) in adipose tissue, specifically the results for epididymal adipose tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, each adipose tissue was collected and the mRNA level of thermogenesis-related factor (UCP1) was measured by real-time qPCR. Statistical analysis was performed as follows: Student's t test *p<0.05, **p<0.01 vs. CTL #p<0.05, ##p<0.01, ###p<0.005 vs. HFD [Figure 8] This figure shows the results of Oil Red O staining of liver tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, liver tissue was obtained and fat accumulation was measured by Oil Red O staining. [Figure 9]This figure shows the results of analyzing the mRNA expression of adipocyte differentiation-related factors (SREBP1, PPARγ, C / EBPα) in liver tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, liver tissue was collected and the mRNA levels of transcription factors involved in adipocyte differentiation (SREBP1, PPARγ, C / EBPα) were measured by real-time qPCR. Statistical analysis was performed as follows: Student's t test ***p<0.005 vs CTL #p<0.05, ##p<0.01, ###p<0.005 vs HFD [Figure 10] This figure shows the results of analyzing the mRNA expression of fibrosis-related factors (αSMA, Col1a1) in liver tissue. Specifically, C57BL / 6J mice (6-week-old, male) were orally administered the test substance once daily for 12 weeks, starting 3 weeks after feeding a high-fat diet. After overnight fasting, liver tissue was obtained and the mRNA levels of liver fibrosis-related factors (αSMA, Col1a1) were measured by real-time qPCR. Statistical analysis was performed as follows: Student's t test ***p<0.005 vs CTL #p<0.05, ##p<0.01, ###p<0.005 vs HFD [Figure 11] FIG. 1 shows the results of SMA immunostaining of liver tissue. [Figure 12] FIG. 1 shows the results of confirming the ability of the SKO-001 strain of the present invention and its isogenic strains KCCM11322 and KCCM12166 to inhibit adipocyte differentiation. [Figure 13] FIG. 1 shows the results of a comparison of the pancreatic lipase enzyme inhibitory activity of the SKO-001 strain of the present invention with that of the homologous strain IDCC 3501. DETAILED DESCRIPTION OF THE INVENTION

[0032] These will be described in detail below. Note that each description and embodiment disclosed in the present invention also applies to other descriptions and embodiments. In other words, all combinations of various elements disclosed in the present invention are included in the present invention. Furthermore, the present invention is not limited to the following specific description.

[0033] Additionally, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein, which equivalents are also to be understood as encompassed by the present invention.

[0034] The present invention is based on the finding that Lactiplantibacillus plantarum strains, particularly the novel strain SKO-001, have new uses.

[0035] Hereinafter, a new use of the Lactiplantibacillus plantarum strain of the present invention according to one embodiment of the present invention will be described in more detail.

[0036] One aspect of the present invention provides a food composition for reducing body fat, comprising at least one selected from the group consisting of the Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0037] The Lactiplantibacillus plantarum strain is a type of lactic acid bacterium, and is a strain that was previously called Lactobacillus plantarum.

[0038] Lactobacillus plantarum in the present invention is a Gram-positive bacillus and one of the most widely distributed lactic acid bacteria, which produces lactic acid by fermenting arabinose, glucose, fructose, galactose, maltose, sucrose, dextran, etc. It is mainly isolated from dairy products, pickled vegetables such as pickles and kimchi, tomatoes, etc. It grows primarily as the sourness of kimchi increases during the later stages of fermentation, and when it becomes dominant, it suppresses the growth of other species. It is generally known to have excellent acid and bile tolerance.

[0039] The Lactiplantibacillus plantarum strain is the SKO-001 strain deposited under accession number KCTC 14816BP, but is not limited thereto.

[0040] In addition, the Lactiplantibacillus plantarum strain has a 16S rRNA sequence represented by SEQ ID NO: 1 and was isolated and identified from Angelica acutiloba, specifically from the roots of Angelica acutiloba, but is not limited thereto.

[0041] The term "culture thereof" as used herein refers to a culture of the Lactiplantibacillus plantarum strain of the present invention, and is a culture product produced by culturing the strain of the present invention in a medium, including, but not limited to, the bacterial cells themselves obtained from the culture and a culture supernatant obtained by filtering and centrifuging the culture.

[0042] "Hybrid product thereof" refers to a lysate of the Lactiplantibacillus plantarum strain of the present invention, and includes any useful substances present in the strain that are released upon disruption of the strain.

[0043] The term "extract thereof" refers to an extract obtained by extracting the Lactiplantibacillus plantarum strain of the present invention with a solvent, and the solvent may be any known solvent and extraction method may be any known method. The extract also includes an extract obtained by extracting the Lactiplantibacillus plantarum strain itself, a culture of the strain, or a disrupted product of the strain.

[0044] The Lactiplantibacillus plantarum strain, its culture, its disruption, or its extract of the present invention is contained in an amount of 0.00001 to 50% by weight of the composition, but is not limited to this amount. Specifically, if it is contained in an amount less than 0.00001% by weight, the effect is insufficient, and if it is contained in an amount greater than 50% by weight, the increase in effect is small compared to the amount used, making it uneconomical.

[0045] "Body fat" in the present invention refers to adipose tissue that constitutes the body and is widely distributed subcutaneously, in the mammary glands, around the kidneys, etc., and is, for example, body fat located in any one selected from the liver, mesentery, around the kidneys, and subcutaneously, but is not limited to these.

[0046] The food composition is for reducing body fat, and the "food" in the present invention may be any food in the usual sense, such as meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, soft drinks, tea, energy drinks, alcoholic beverages, vitamin complexes, functional foods, and health foods.

[0047] The food compositions of the present invention include functional food compositions. When the strain is used as an additive in a functional food composition, it may be added directly or in combination with other foods or food ingredients, and may be used in a conventional manner. The amount of active ingredient to be added is determined appropriately depending on the intended use, such as prevention, health, or treatment.

[0048] The dosage form of the food may be any form of powder, granules, pills, tablets, or capsules, as well as any general food or drink form.

[0049] The type of food is not particularly limited, and examples of foods to which the substance may be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products such as ice cream, various soups, soft drinks, tea, energy drinks, alcoholic beverages, vitamin complexes, etc., and any food in the usual sense may be used.

[0050] Generally, when producing a food or beverage, the strain is added in an amount of 0.0001 to 50 parts by weight or less, specifically 0.1 to 20 parts by weight, per 100 parts by weight of the raw material. However, for long-term intake for health and hygiene purposes or for health regulation purposes, the amount may be less than the above range. Since there are no safety issues, the active ingredient may be used in an amount greater than the above range, and is not limited to the above range.

[0051] Among the functional foods of the present invention, beverages may contain various flavoring agents and natural carbohydrates as additional ingredients, similar to conventional beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, or sugar alcohols such as xylitol, sorbitol, and erythritol. Examples of sweeteners that can be used include natural sweeteners such as thaumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrates is approximately 0.01 to 0.04 g, specifically approximately 0.02 to 0.03 g, per 100 mL of the beverage of the present invention.

[0052] In addition to the above, the functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloids, thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonation agents used in carbonated beverages. The functional food composition of the present invention may also contain fruit pulp for producing natural fruit juice, fruit juice beverages, and vegetable beverages. These ingredients may be used alone or in combination. The proportion of these additives is not limited, but is typically selected from the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the functional food composition of the present invention.

[0053] One aspect of the present invention provides a food composition for preventing or improving obesity, comprising at least one selected from the group consisting of the Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0054] The terms "Lactiplantibacillus plantarum strain," "culture thereof," "disruption thereof," "extract thereof," and "food composition" are as described above.

[0055] In the present invention, "obesity" refers to a state in which a person consumes food in excess of the amount of energy required by the human body, resulting in the consumption of energy and the remaining energy being converted into fat and accumulated in the body in the form of neutral fat. Such obesity can lead to various chronic diseases such as high blood pressure, arteriosclerosis, and diabetes.

[0056] The food composition of the present invention described above may be used to prevent or improve obesity.

[0057] In the present invention, "prevention" means any action of suppressing or delaying the symptoms of obesity by ingesting or administering at least one selected from the group consisting of the strain of the present invention, its culture, its disruption, and its extract.

[0058] In the present invention, "improvement" refers to any action that improves or favorably changes the symptoms of obesity by ingesting or administering at least one selected from the group consisting of the strain of the present invention, its culture, its disruption, and its extract.

[0059] As a specific example, the Lactiplantibacillus plantarum SKO-001 strain may lower the level of low-density lipoprotein cholesterol (LDL-cholesterol) in the blood. Generally, low-density lipoprotein cholesterol is known as bad cholesterol, and if the level of low-density lipoprotein cholesterol deviates from the normal range, the probability of developing arteriosclerosis, which blocks blood vessels, increases, and the probability of developing brain, heart, and cardiovascular diseases increases. Therefore, it is very important to lower the level of low-density lipoprotein cholesterol.

[0060] In another specific example, the Lactiplantibacillus plantarum SKO-001 strain may lower blood leptin levels and increase blood adiponectin levels. Leptin is a major hormone secreted by adipocytes to regulate appetite and is found in many animals. The more obese an animal, the higher the amount of leptin in its body, which reduces appetite. On the other hand, adiponectin is a hormone secreted in greater amounts in lean animals than obese animals and is known to have the opposite effect to leptin. The novel strain of the present invention can prevent, improve, or treat obesity by lowering blood leptin levels and increasing adiponectin levels.

[0061] In yet another embodiment, the bacterial strain of the present invention may inhibit adipocyte differentiation and fat accumulation. Specifically, it may reduce weight gain without affecting appetite reduction. In particular, unlike conventional drug therapies for treating obesity, which have been problematic due to the many side effects they cause, such as appetite reduction and depression and rebound phenomenon associated with obesity treatments using foods and drugs that suppress fat absorption, the novel bacterial strain of the present invention has the effect of reducing body fat and weight gain without reducing appetite and does not cause the side effects of conventional foods and drugs, making it useful for improving obesity.

[0062] Therefore, the present invention provides a food composition or functional food composition for reducing body fat or preventing or improving obesity, which contains the Lactiplantibacillus plantarum SKO-001 strain, a culture thereof, a disrupted product thereof, or an extract thereof.

[0063] One aspect of the present invention provides a pharmaceutical composition for preventing or treating metabolic diseases, comprising at least one selected from the group consisting of the Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0064] One aspect of the present invention provides a functional food composition for preventing or improving metabolic diseases, comprising at least one selected from the group consisting of the Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0065] The terms "Lactiplantibacillus plantarum strain," "culture thereof," "disruption thereof," and "extract thereof" are as described above.

[0066] In the present invention, the term "metabolic disease" is a general term for diseases caused by metabolic disorders in the body, and specifically includes at least one selected from the group consisting of obesity, diabetes, insulin resistance, dyslipidemia, hypercholesterolemia, arteriosclerosis, hepatic steatosis, fatty liver, and cardiovascular disease, but is not limited to these.

[0067] Here, diabetes is used to include both insulin-dependent diabetes (type 1 diabetes) and non-insulin-dependent diabetes (type 2 diabetes), and also to include diabetes caused by damage to the pancreas due to other diseases, such as diabetes caused by hyperthyroidism, hyperadrenocorticism, growth hormone excess or catecholamine excess, and gestational diabetes.

[0068] "Prevention" in the present invention means any action of suppressing or delaying metabolic disorders by administering the pharmaceutical composition of the present invention.

[0069] "Treatment" in the present invention means any action that improves or beneficially alters the symptoms of a metabolic disorder by administering the pharmaceutical composition of the present invention.

[0070] The compositions of the present invention, including the pharmaceutical composition, may contain, in addition to the above ingredients, one or more active ingredients having the same or similar functions.

[0071] The pharmaceutical composition of the present invention may further contain a pharmaceutically acceptable carrier in addition to the pharmaceutical composition of the present invention.

[0072] In the pharmaceutical composition of the present invention, the novel strain, its culture, disruption thereof, or extract thereof is contained in an amount of 0.00001% to 99.99% by weight, specifically 0.1% to 90% by weight, more specifically 0.1% to 70% by weight, and even more specifically 0.1% to 50% by weight, based on the total weight of the pharmaceutical composition, but is not limited thereto and may be varied as appropriate depending on the condition of the subject, the specific type and progression of the disease, etc. If necessary, it may constitute the total weight of the pharmaceutical composition.

[0073] The pharmaceutical compositions of the present invention can be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, and sterile injection solutions by conventional methods, and may contain suitable carriers, excipients, or diluents that are commonly used in the manufacture of pharmaceutical compositions for formulation.

[0074] The carrier, excipient, or diluent may include various compounds or mixtures thereof, including lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.

[0075] When formulated, the preparation may be prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc.

[0076] Oral solid formulations may be prepared by mixing the strain with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to the usual excipients, lubricants such as magnesium stearate and talc may also be used.

[0077] Oral liquid preparations include suspensions, oral liquids, emulsions, syrups, etc., and in addition to the usual diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavoring agents, preservatives, etc. are used.

[0078] Parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cocoa butter, laurin butter, and glycerogelatin.

[0079] The preferred dosage of the pharmaceutical composition of the present invention varies depending on the patient's condition and weight, the severity of the disease, the drug form, the route of administration, and the duration of administration, and can be appropriately selected by those skilled in the art. However, to achieve the desired effect, it is recommended to administer 0.0001 to 2,000 mg / kg per day, specifically 0.001 to 2,000 mg / kg per day. The dosage may be administered once a day or in divided doses. However, the present invention is not limited to the above dosage.

[0080] The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, etc. by various routes, including oral, rectal, or intravenous, intramuscular, subcutaneous, intrauterine, dura, or intracerebroventricular injection.

[0081] In the present invention, the term "individual" refers to any animal, including humans, that has or is at risk of developing obesity or metabolic disease symptoms. The animal includes not only humans but also mammals requiring treatment for similar symptoms, such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, and cats, but is not limited to these. Individuals requiring the composition of the present invention may be humans or non-human individuals, but are not limited to these. One aspect of the present invention provides a feed composition for preventing or improving obesity, comprising at least one species selected from the group consisting of the Lactiplantibacillus plantarum strain, a culture thereof, a lysate thereof, and an extract thereof.

[0082] Another aspect of the present invention provides a feed composition for preventing or ameliorating metabolic diseases, comprising at least one selected from the group consisting of the Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

[0083] The terms "Lactiplantibacillus plantarum strain," "culture thereof," "disintegrate thereof," "extract thereof," "obesity," "prevention," "amelioration," and "metabolic disease" are as described above.

[0084] The feed composition of the present invention is an alternative to conventional animal antibiotics and has the effects of suppressing the growth of harmful pathogenic microorganisms, thereby improving the health of animals, improving weight gain and meat quality, and increasing milk production and immunity. The feed composition can be prepared in the form of fermented feed, formulated feed, pellets, silage, etc.

[0085] The fermented feed can be produced by fermenting organic matter by adding various microorganisms or enzymes other than the above strains, and compound feed can be produced by mixing various general feeds with the above strains. Pellet-form feed can be produced by applying heat and pressure to the compound feed in a pelleting machine, and silage can be produced by fermenting green forage with microorganisms. Wet fermented feed can be produced by collecting and transporting organic matter such as food waste, sterilizing it, mixing it with excipients to adjust the moisture content in a predetermined ratio, and then fermenting it at a temperature suitable for fermentation for 24 hours or more, adjusting the moisture content to about 70%. Fermented and dried feed can be produced by further drying the wet fermented feed and adjusting the moisture content to about 30% to 40%.

[0086] The feed composition may be included in the form of a feed additive. [Example]

[0087] The present invention will be described in more detail below with reference to examples. These examples are intended to explain the present invention more specifically, but the present invention is not limited to these examples.

[0088] Example 1 Preparation of lactipranti Bacillus plantarum SKO-001 strain The present invention, Lactiplantibacillus plantarum SKO-001 strain (accession number KCTC 14816BP), was isolated and identified from Angelica sinensis (Angelica acutiloba).

[0089] Specifically, to isolate the strain of the present invention, Angelica gigas Nakai roots were used as samples. First, the roots were cleaned of soil and then washed three times with sterile distilled water. The root surface was then wiped with sterile filter paper, and the filter paper was diluted with sterile water and homogenized in a stomacher for 5 minutes. The homogenized sample was diluted appropriately and then smeared on MRS solid medium and cultured at 37°C for 48 hours. The resulting colonies were differentiated by morphology and color and purified again. To confirm the lineage of the isolated strain, 16S rRNA sequence analysis confirmed 99% sequence identity with Lactiplantibacillus plantarum.

[0090] Furthermore, for more accurate classification and identification, whole genome analysis of the isolated strain was performed at Chung Lab (Korea). Specifically, the whole genome sequence of the isolated strain was compared with that of a reference strain selected from the EzBioCloud Database. The average nucleotide identity (ANI) of the genome sequence to that of the reference strain was 99.02%, and the isolate was ultimately identified as Lactobacillus plantarum subsp. plantarum.

[0091] Therefore, the strain isolated from Angelica sinensis through the above process was named Lactiplantibacillus plantarum SKO-001 and deposited with the Korea Institute of Bioscience and Biotechnology's Biological Resource Center (Korean Collection for Type Cultures) on December 8, 2021, under accession number KCTC 14816BP.

[0092] Meanwhile, the strain of the present invention was pre-cultured and then cultured for 16 to 24 hours in a culture medium containing glucose, yeast extract, peptone, polysorbate 80, magnesium sulfate, etc., and then the cells were harvested, suspended in a lyoprotectant, and then lyophilized to produce a powder sample.

[0093] Example 2 Creation of a high-fat diet-fed mouse obesity model and confirmation of the body fat reducing effect of Lactipranchibacillus plantarum SKO-001 2-1. Establishment of a high-fat diet mouse obesity model and sample administration The body fat reducing effect was confirmed using the strain of the present invention, Lactiplantibacillus plantarum SKO-001.

[0094] Specifically, the animals used in the experiment were C57BL / 6J mice (male, 5 weeks old) with high-fat diet-induced obesity. They were purchased from Orient Bio and acclimated for one week before use. The normal control group (CTL) was fed a standard diet, while the obesity-induced group (HFD) was fed only a high-fat diet (60% fat; Saeronbio Inc., Research Diets) for three weeks. Body weight changes, food intake, behavior, etc. were observed weekly over the three weeks, and body weight was measured again immediately before administration of the test substance (SKO-001). After that, the treatment groups were organized as shown in Table 1, minimizing weight deviation within each group (n = 10). The sample-administered group was fed a high-fat diet and administered a low dose of SKO-001 (5 × 10 9 CFU / day), medium dose (1×10 10 CFU / day), high dose (2×10 10 The test animals were dissolved in autoclaved tap water at a concentration of 100 mg / day (CFU / day) and orally administered at the same time every day for 12 weeks.

[0095] These are summarized in Table 1 below.

[0096] [Table 1]

[0097] 2-2. Analysis of feed intake and body weight changes Body weight change and food intake were measured once a week throughout the entire experimental period, and the results are shown in Figures 1 and 2, respectively.

[0098] As shown in Figure 1, the high-fat diet group showed a significant increase in body weight compared to the normal control group (CTL) that received a general diet, confirming the obesity-inducing effect of a high-fat diet. Furthermore, when SKO-001 of the present invention was orally administered once daily to high-fat diet mice for 12 weeks, a statistically significant weight loss effect was observed in the high-dose SKO-001 group (HFD / SKO-001-H) starting from the sixth week of sample substance administration.

[0099] Next, as shown in Figure 2, the intake of regular chow was significantly higher, but when the feed intake of the obesity-induced group (HFD) and the SKO-001-administered group was compared, it was confirmed that there was no significant change in feed intake during the administration period. These results indicate that SKO-001 administration does not affect appetite.

[0100] 2-3. Measurement of body fat mass After 12 weeks of test substance administration, body fat mass was measured non-invasively using a Minispec (Mini-spec, LF-90II, Bruker Optics GmbH, Germany). The results are shown in Figure 3.

[0101] As a result, as shown in Figure 3, it was confirmed that the increased body fat mass in the obesity-induced group (HFD) was significantly reduced by high-dose administration of SKO-001 compared to the normal control group (CTL). In particular, in the high-dose SKO-001 administration group (SKO-001-H), body fat mass and final body weight were reduced, but no effect on whole body lean mass was observed. Therefore, it was confirmed that SKO-001 of the present invention has the effect of selectively reducing only fat mass.

[0102] 2-4. Analysis of blood energy metabolism regulatory factors and lipid concentrations To confirm the changes in blood energy metabolism regulatory factors (insulin, adiponectin, leptin) and lipid (total cholesterol, LDL-c, HDL-c, TG, FFA) concentrations due to SKO-001 administration, serum was separated from blood collected from mice in each group after 12 weeks of test substance administration and used in the experiment. The concentrations of these factors were measured using Mouse HMW & Total adiponectin ELISA (47-ADPMS-E01, ALPCO), Mouse insulin ELISA (80-INSMS-E01, ALPCO), Mouse leptin ELISA kit (KTE71186, Abbkine), Cholesterol Assay Kit-HDL and LDL / VLDL (ab65390, Abcam), CheKine™ Triglyceride (TG) colorimetric assay kit (KTB2200, Abbkine), Chekine™ Total cholesterol (TC) colorimetric assay kit (KTB2220, Abbkine), and Free Fatty Acid Assay Kit (ab65341, Abcam). The results are shown in Figure 4.

[0103] First, blood levels of insulin, adiponectin, and leptin were measured to confirm the effects on energy metabolism-related factors. As shown in Figure 4a, SKO-001 administration significantly reduced insulin and leptin levels compared to the obesity-induced group (HFD). In contrast, SKO-001 administration significantly increased levels of adiponectin, an obesity-suppressing hormone that was reduced by a high-fat diet. Therefore, the anti-obesity effect of SKO-001 was confirmed.

[0104] Next, to confirm whether the novel strain SKO-001 of the present invention has an effect of improving lipid profile, the levels of total cholesterol, LDL-c, HDL-c, TG, and FFA, which are indicators of lipid content, were measured. As shown in Figure 4b, the levels of total cholesterol, LDL cholesterol, TG, and FFA were significantly reduced in the SKO-001 high-dose administration group (SKO-001-H) compared to the obesity-induced group (HFD). Therefore, it was confirmed that the novel strain SKO-001 of the present invention has an obesity-suppressing effect.

[0105] 2-5. Morphological analysis of adipose tissue (H&E staining) To investigate the intracellular adipocyte size in subcutaneous, visceral, and epididymal adipose tissue, tissues were excised, washed with PBS, and then fixed in 10% formalin. Paraffin blocks were then prepared and stained with hematoxylin and eosin (H&E). The tissues were then observed under a microscope (Zeiss Axio imager z1 fluo-microscope) and photographed.

[0106] As a result, as shown in Figure 5, it was confirmed that the adipocyte size increased by a high-fat diet in all three types of adipose tissue was significantly reduced in a dose-dependent manner by administration of the novel strain SKO-001 of the present invention, indicating an inhibitory effect on fat accumulation.

[0107] 2-6. Confirmation of the regulation of adipocyte differentiation-related factor expression in adipose tissue After 12 weeks of treatment with the test substance, we examined changes in mRNA expression of transcription factors (SREBP1, PPARγ, and C / EBPα) important for adipocyte differentiation. To do so, we isolated three types of adipose tissue (subcutaneous fat, visceral fat, and epididymal fat) and extracted RNA from the tissues using the Easy Blue kit. cDNA was synthesized from 100 ng of RNA and then subjected to real-time qPCR using the following primer sequence: SREBP1: forward (5'- CGACTACATCCGCTTCTTGCAG-3') and reverse (5'- CCTCCATAGACACATCTGTGCC-3) PPARγ: forward (5'- GTACTGTCGGTTTCAGAAGTGCC-3') and reverse (5'ATCTCCGCCAACAGCTTCTCCT-3') C / EBPα: forward (5'- GCAAAGCCAAGAAGTCGGTGGA-3') and reverse (5'- CCTTCTGTTGCGTCTCCACGTT-3')

[0108] As a result, as shown in Figure 6, it was confirmed that the mRNA expression levels of SREBP1, PPARγ, and C / EBPα, which were increased by a high-fat diet, were significantly reduced by administration of SKO-001 in all three types of adipose tissue. This suggests that the novel bacterial strain SKO-001 of the present invention exerts excellent anti-obesity activity by suppressing the expression of transcription factors (SREBP1, PPARγ, and C / EBPα) that promote adipocyte differentiation.

[0109] 2-7. Confirmation of regulation of thermogenesis-related factor (UCP1) expression in adipose tissue To confirm the browning effect of SKO-001 administration in three types of adipose tissue (subcutaneous fat, visceral fat, and epididymal fat), RNA was extracted from the tissues, cDNA was synthesized, and real-time qPCR was then performed using UCP1 primers. UCP1: forward 5'-CAAAAACAGAAGGATTGCCGAAA-3' and reverse 5'-TCTTGGACTGAGTCGTAGAGG-3'

[0110] As a result, as shown in Figure 7, it was confirmed that the mRNA expression of UCP1, which plays an important role in the browning effect, was significantly increased by administration of SKO-001 in all three types of adipose tissue. This suggests that the novel bacterial strain SKO-001 of the present invention exerts excellent anti-obesity activity by promoting thermogenesis.

[0111] 2-8. Suppression of hepatic lipid synthesis by SKO-001 in liver tissue Because a high-fat diet is known to cause nonalcoholic liver lipid disorders, we evaluated whether SKO-001 is effective in suppressing fat accumulation in liver tissue and liver fibrosis. The results are shown in Figure 8.

[0112] As a result, when the degree of lipid accumulation in liver tissue was compared using Oil Red O staining, significantly more fat globules were observed in the obesity-induced group (HFD) than in the normal diet group (CTL), as shown in Figure 8. However, in the HFD group that received SKO-001, fat globules decreased in an SKO-001 concentration-dependent manner.

[0113] Furthermore, a comparison of the mRNA expression of transcription factors (SREBP1, PPARγ, and C / EBPα) that promote adipocyte differentiation in liver tissue is shown in Figure 9. As a result, it was confirmed that, as in the case of adipose tissue, the expression of SREBP1 and PPARγ mRNA, which was increased by a high-fat diet, was significantly suppressed by administration of SKO-001.

[0114] A comparison of the mRNA expression of αSMA and Col1a1, which are markers associated with liver tissue fibrosis, is shown in Figure 10. As a result, it was confirmed that administration of SKO-001 significantly reduced αSMA and Col1a1, and was effective in improving liver fibrosis.

[0115] Furthermore, αSMA immunostaining of liver tissues revealed that, as shown in Figure 11, αSMA levels were increased in the obesity-induced group (HFD) compared to the normal diet group (CTL), consistent with the real-time qPCR results, and were confirmed to be reduced in a dose-dependent manner by administration of the novel bacterial strain SKO-001 of the present invention.

[0116] In conclusion, it is clear that the novel bacterial strain SKO-001 of the present invention reduces lipid accumulation not only in adipose tissue but also in liver tissue and by suppressing the expression of factors promoting adipocyte differentiation.

[0117] Example 3 Comparison of the body fat reduction effects of Lactiplantibacillus plantarum SKO-001 with those of the same strains KCCM11322, KCCM12166, and IDCC 3501 To confirm whether the Lactobacillus plantarum SKO-001 strain of the present invention has superior body fat reduction and anti-obesity activities compared to other strains of the same species, its ability to inhibit adipocyte differentiation and its pancreatic lipase enzyme inhibitory activity were directly compared with those of three other strains of the same species (KCCM11322, KCCM12166, and IDCC3501).

[0118] 3-1. Comparison of ability to suppress adipocyte differentiation A comparative experiment was carried out to measure the degree of inhibition of differentiation of mouse preadipocytes (3T3-L1) by two strains (KCCM11322 and KCCM12166) of the same species as Lactipranchibacillus plantarum SKO-001 of the present invention. The Lactipranchibacillus plantarum KCCM11322 and KCCM12166 (type strain) used as comparative strains were provided by the Korea Center for Microorganisms (KCCM).

[0119] The experiment details are as follows.

[0120] The degree of fat globule formation by LactipranchiBacillus plantarum treatment was confirmed by Oil red O staining. First, 8 × 10 3T3-L1 cells were plated in a 6-well plate. 4 The cells were aliquoted at 1000 cells / mL and differentiated for 8 days. Over the course of the 8 days, they were treated with 4% bacterial lysate. They were then fixed with 4% paraformaldehyde for 30 minutes at room temperature, washed with 1X PBS, and stained with Oil Red O solution for 1 hour at room temperature. The stained fat globules were then washed again with 1X PBS and observed under a microscope. The stained fat globules were then extracted with 100% isopropanol, and their absorbance was measured at 540 nm using a microplate reader. The protein concentration of each lysate was then corrected. The protein concentration of each isogeneic bacterial strain was then determined relative to the fat accumulation in the SKO-001-treated group, which was defined as 100%. Statistical analysis was performed as follows: Student's test **p<0.01 vs. SKO-001

[0121] As a result, as shown in Figure 12, the fat accumulation amounts of the comparative strains KCCM11322 and KCCM12166 were 271.1% and 369.2%, respectively, confirming a significant difference of 2.7 to 3.6 times the fat accumulation rate of the SKO-001 strain of the present invention. These results demonstrate that the SKO-001 strain of the present invention has significantly superior fat accumulation inhibitory activity compared to the homologous comparative strains KCCM11322 and KCCM12166, and further confirmed its excellent body fat reduction effect by suppressing the adipocyte differentiation activity of preadipocytes.

[0122] 3-2. Pancreatic lipase enzyme inhibitory activity test The degree of inhibition of pancreatic lipase enzyme inhibitory activity was compared between the present invention Lactiplantibacillus plantarum SKO-001 and a strain of the same species isolated from kimchi (IDCC 3501).

[0123] Specifically, the inhibitory activity of pancreatic lipase by Lactipranchibacillus plantarum treatment was measured based on the inhibition of the hydrolysis of p-nitrophenyl palmitate (pNPP) to p-nitrophenyl. The culture medium of the strain was added to 10 mM pNPP and 10 mg / mL pancreatic lipase, and the mixture was incubated at 37°C for 30 minutes. The reaction mixture was then placed on ice for 10 minutes to terminate the enzymatic reaction. The mixture was then centrifuged at 13,000 rpm for 1 minute to obtain 100 μL of supernatant, and the absorbance was measured at 405 nm using a microplate reader. Orlistat was used as a positive control. Pancreatic lipase inhibitory activity was expressed as a percentage reduction in absorbance between the sample-treated and untreated groups. Statistical analysis was performed as follows: Student's test ***p<0.001 vs. SKO-001

[0124] As a result, as shown in Figure 13, the pancreatic lipase inhibitory activities of orlistat used as a positive control and the comparative strain IDCC 3501 were confirmed to be 96.4% and 68.7%, respectively. In contrast, the pancreatic lipase inhibitory activity of SKO-001 of the present invention was 92.6%, which was comparable to the positive control and showed a relatively high inhibitory effect compared to the IDCC 3501 strain.

[0125] These results indicate that the SKO-001 strain of the present invention has significantly superior pancreatic lipase inhibitory activity compared to its homologous strain, IDCC3501, and suggest that the novel SKO-001 strain directly suppresses pancreatic lipase activity, thereby reducing fat absorption into the body and thereby achieving an excellent effect in reducing body fat.

[0126] From the above description, those skilled in the art to which the present invention pertains will understand that the present invention can be embodied in other specific forms without changing the technical spirit or essential features thereof. It should be understood that the above examples are merely illustrative and not limiting. The present invention should be construed as including all modifications and variations derived from the meaning and scope of the claims, rather than the specification, and their equivalents.

Claims

1. A food composition for reducing body fat, comprising at least one member selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

2. 2. The food composition for reducing body fat according to claim 1, wherein the bacterial strain is Lactiplantibacillus plantarum SKO-001 strain deposited under accession number KCTC 14816BP.

3. The food composition for reducing body fat according to claim 1 , wherein the strain has a 16S rRNA sequence represented by SEQ ID NO:

1.

4. A food composition for preventing or improving obesity, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

5. A pharmaceutical composition for preventing or treating obesity, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

6. A feed composition for preventing or improving obesity, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

7. A food composition for preventing or improving metabolic diseases, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

8. 8. The food composition for preventing or ameliorating metabolic diseases according to claim 7, wherein the metabolic disease is at least one selected from the group consisting of obesity, diabetes, insulin resistance, dyslipidemia, hypercholesterolemia, arteriosclerosis, hepatic steatosis, fatty liver, and cardiovascular disease.

9. A pharmaceutical composition for preventing or treating metabolic diseases, comprising at least one selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

10. A feed composition for preventing or improving metabolic diseases, comprising at least one member selected from the group consisting of a Lactiplantibacillus plantarum strain, a culture thereof, a disrupted product thereof, and an extract thereof.

Images